Tumor markers are a heterogeneous group of substances released by cancer cells into
bloodstream, but also expressed by healthy tissues. Thus, very small concentrations can be …

Clinical practice guidelines (CPGs) on screening, surveillance, and treatment of several
diseases recommend the selective use of biomarkers with central role in clinical decision …

Early diagnosis and monitoring are essential for the effective treatment and survival of
patients with different types of malignancy. To this end, the accurate and sensitive …

Human epididymis protein 4 (HE4) is an ovarian cancer marker. Various cut-off values of the
marker in blood are recommended, depending on the method used for its determination. An …

Objectives Reliable biological variation (BV) data are required for the clinical use of tumor
markers in the diagnosis and monitoring of treatment effects in cancer. The European …

Objectives Few studies have reported on delta checks for tumour markers, even though
these markers are often evaluated serially. Therefore, this study aimed to establish a …

Background: Human epididymis secretory protein 4 (HE4) is a new ovarian cancer
biomarker. The factors influencing HE4 levels are not clear, and the reference data in China …

Objective Human epididymis protein 4 (HE4) is a validated, complementary biomarker to
cancer antigen 125 (CA125) for high grade serous ovarian carcinoma (HGSC). Currently …

Diagnostics based on the determination of biomarkers in body fluids will be more successful
when several biomarkers are determined. A multiple-array SPRi biosensor for the …

Background The increased role of preventive medicine in healthcare and the rapid
technological advancements, have deeply changed the landscape of laboratory medicine. In …